#United States #Seattle #SeptiCyte RAPID #Immunexpress #sepsis detection

Clinical Utility of SeptiCyte® RAPID in Sepsis Detection

Recent findings have brought to light the effectiveness of the SeptiCyte® RAPID test in recognizing sepsis early in patients recovering from major abdominal surgeries. Published in the journal Infection, the study demonstrates how this innovative approach could revolutionize diagnoses in Intensive Care Units (ICUs).

Victims of sepsis, a life-threatening response to infection, often experience a silent but rapid decline in health that can lead to serious complications or even death. Early identification of this condition is crucial for improving patient outcomes, especially for those who have undergone significant surgical interventions. Traditional diagnostic methods can be time-consuming and may lead to delayed treatment, making the need for a reliable and swift solution evident.

The Significance of SeptiCyte® RAPID

According to Dr. Maik von der Forst from the Medical Faculty Heidelberg, who contributed to the study, using host response assays like SeptiCyte RAPID represents a promising path toward quicker diagnosis. In their research, the results from SeptiCyte RAPID were shown to align with evaluations made by blinded sepsis experts, thus validating its clinical utility.

The study cohort included surgical patients in a high-level ICU setting, where SeptiCyte RAPID produced higher mean scores, identified as SeptiScores®, for patients diagnosed post-hoc with sepsis. These scores were recorded both within three hours of admission and 24 hours later, demonstrating consistent accuracy regardless of infection sources. More strikingly, SeptiScore effectively distinguished sepsis patients from those exhibiting inflammation due to surgical recovery, outperforming existing laboratory markers and severity assessments.

Enhanced Diagnostic Accuracy

Roy Davis, MD, Chief Medical Officer at Immunexpress, remarked that the SeptiCyte RAPID tool has proven effective in swiftly diagnosing or ruling out sepsis amongst complex hospitalized individuals. The study ultimately illustrates that SeptiCyte RAPID can significantly contribute to a comprehensive diagnostic algorithm that incorporates clinical evaluations, biomarkers, and microbiological findings, crucial in managing sepsis effectively.

Moreover, the study indicated that prior antibiotic treatment did not adversely affect the accuracy of SeptiCyte RAPID, and the correlation between test results and blood culture positivity was notably high.

About SeptiCyte® RAPID

This molecular test utilizes reverse transcription polymerase chain reaction (RT-PCR) to assess the expression levels of host response genes from whole blood samples. Operating in conjunction with clinical assessments, vital signs, and laboratory results, SeptiCyte RAPID aids in differentiating between infection-positive sepsis and infection-negative systemic inflammation response syndromes. The test presents results capable of categorizing the likelihood of sepsis through a SeptiScore indicated within four distinct bands, simplifying interpretation for healthcare providers.

Currently, SeptiCyte RAPID is CE Marked for diagnostic use in the EU and has received FDA clearance for application in hospitalized patients suspected of sepsis since November 2021. This technology emphasizes swift patient management, allowing healthcare professionals to make timely decisions crucial for patient survival.

Conclusion

Immunexpress, the company behind SeptiCyte®, is based in Brisbane and Seattle, committing to enhancing outcomes for patients with suspected sepsis by offering advanced diagnostic solutions. The ability to identify and address sepsis early can profoundly impact the clinical trajectory for post-operative patients, showcasing SeptiCyte RAPID as a powerful ally in the fight against this medical emergency.

For further information, visit Immunexpress.